384 related articles for article (PubMed ID: 26289641)
1. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
[TBL] [Abstract][Full Text] [Related]
2. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
[TBL] [Abstract][Full Text] [Related]
6. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
[No Abstract] [Full Text] [Related]
7. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
[TBL] [Abstract][Full Text] [Related]
8. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
[No Abstract] [Full Text] [Related]
9. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
Pi Y; Wang J; Zhou H; Ye X; Sun X; Liu L; Pan X; Wang Z
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3033-3041. PubMed ID: 35852619
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Li Z; Wang Y; Wang J; Zhang J; Wang Z
Leuk Lymphoma; 2018 Jan; 59(1):77-84. PubMed ID: 28573910
[TBL] [Abstract][Full Text] [Related]
11. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
Chen L; Wang J; Wang Z
Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
Jin Z; Wang Y; Wei N; Wang Z
Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
[TBL] [Abstract][Full Text] [Related]
13. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children.
Cheng CN; Chu WY; Chang KC; Chen JS
J Formos Med Assoc; 2022 Nov; 121(11):2351-2355. PubMed ID: 35123848
[TBL] [Abstract][Full Text] [Related]
16. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
Song Y; Wang J; Wang Y; Wang Z
Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.
Marsh RA; Jordan MB; Talano JA; Nichols KE; Kumar A; Naqvi A; Vaiselbuh SR;
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786410
[TBL] [Abstract][Full Text] [Related]
18. First prospective clinical trial in adult HLH.
La Rosée P
Blood; 2015 Nov; 126(19):2169-71. PubMed ID: 26542249
[No Abstract] [Full Text] [Related]
19. Treatment of hemophagocytic lymphohistiocytosis.
Wang Y; Wang Z
Curr Opin Hematol; 2017 Jan; 24(1):54-58. PubMed ID: 27755125
[TBL] [Abstract][Full Text] [Related]
20. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
Meng G; Wang Y; Wang J; Wang Z
Leuk Lymphoma; 2021 Apr; 62(4):854-860. PubMed ID: 33225788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
